Advertisement

Comment on: ‘Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer’ by De Vincentis et al

Published:December 03, 2020DOI:https://doi.org/10.1016/j.ejca.2020.09.041
      We were very impressed by the interesting and intriguing work of van der Doelen et al. [
      • van der Doelen M.J.
      • Isaacsson Velho P.
      • Slootbeek P.H.J.
      • Pamidimarri Naga S.
      • Bormann M.
      • van Helvert S.
      • et al.
      Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
      ] recently published in your Journal . This inspires some considerations that we would gladly share with the scientific community.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • van der Doelen M.J.
        • Isaacsson Velho P.
        • Slootbeek P.H.J.
        • Pamidimarri Naga S.
        • Bormann M.
        • van Helvert S.
        • et al.
        Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
        Eur J Canc. 2020; 136 (Oxford, England : 1990): 16-24https://doi.org/10.1016/j.ejca.2020.05.001
        • Terrisse S.
        • Karamouza E.
        • Parker C.C.
        • Sartor A.O.
        • James N.D.
        • Pirrie S.
        • et al.
        Overall survival in men with bone metastases from castration-resistant prostate cancer treated with bone-targeting radioisotopes: a meta-analysis of individual patient data from randomized clinical trials.
        JAMA Oncol. 2020; 6: 206-216https://doi.org/10.1001/jamaoncol.2019.4097
        • Ricci M.
        • Frantellizzi V.
        • Bulzonetti N.
        • De Vincentis G.
        Reversibility of castration resistance status after Radium-223 dichloride treatment: clinical evidence and Review of the literature.
        Int J Radiat Biol. 2018; : 1-29https://doi.org/10.1080/09553002.2019.1558301
        • Casarin S.
        • Dondossola E.
        An agent-based model of prostate Cancer bone metastasis progression and response to Radium223.
        BMC Canc. 2020; 20: 605https://doi.org/10.1186/s12885-020-07084-w
        • Antonarakis E.S.
        • Lu C.
        • Luber B.
        • Liang C.
        • Wang H.
        • Chen Y.
        • et al.
        Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide.
        Eur Urol. 2018; 74: 218-225https://doi.org/10.1016/j.eururo.2018.01.035
        • Isaacsson Velho P.
        • Qazi F.
        • Hassan S.
        • Carducci M.A.
        • Denmeade S.R.
        • Markowski M.C.
        • et al.
        Efficacy of radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects.
        Eur Urol. 2019; 76: 170-176https://doi.org/10.1016/j.eururo.2018.09.040
        • De Vincentis G.
        • Follacchio G.A.
        • Frantellizzi V.
        • Liberatore M.
        • Monteleone F.
        • Cortesi E.
        Prostate-specific antigen flare phenomenon during 223Ra-dichloride treatment for bone metastatic castration-resistant prostate cancer: a case report.
        Clin Genitourin Canc. 2016; 14: e529-e533https://doi.org/10.1016/j.clgc.2016.04.014
        • Morris M.J.
        • Loriot Y.
        • Sweeney C.J.
        • Fizazi K.
        • Ryan C.J.
        • Shevrin D.H.
        • et al.
        Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.
        Eur J Canc. 2019; 114 (Oxford, England : 1990): 107-116https://doi.org/10.1016/j.ejca.2019.04.007
        • Frantellizzi V.
        • Costa R.
        • Mascia M.
        • Spanu A.
        • Farcomeni A.
        • Licari M.
        • et al.
        Primary radical prostatectomy or ablative radiotherapy as protective factors for patients with mCRPC treated with radium-223 dichloride: an Italian multicenter study.
        Clin Genitourin Canc. 2020; 18: 185-191https://doi.org/10.1016/j.clgc.2019.10.009
        • Frantellizzi V.
        • Monari F.
        • Mascia M.
        • Costa R.
        • Rubini G.
        • Spanu A.
        • et al.
        Validation of the 3-variable prognostic score (3-PS) in mCRPC patients treated with (223)Radium-dichloride: a national multicenter study.
        Ann Nucl Med. 2020; https://doi.org/10.1007/s12149-020-01501-7

      Linked Article